Table 1.
Patient demographics and disease characteristics at baseline (ITT)
| CLNP/BPO 3% (n = 172) | ADA + CLNP (n = 177) | |
|---|---|---|
| Age, mean (SD) | 20.3 (5.9) | 19.8 (4.9) |
| <16 years, n (%) | 41 (23.8) | 36 (20.3) |
| 16–20 years, n (%) | 61 (35.5) | 68 (38.4) |
| >20 years, n (%) | 70 (40.7) | 73 (41.2) |
| Sex, n (%) | ||
| Female | 97 (56.4) | 110 (62.1) |
| Male | 75 (43.6) | 67 (37.9) |
| Weight (kg), mean (SD) | 57.0 (9.6) | 54.8 (9.0) |
| Lesion counts at baseline, mean (SD) | ||
| TL | 102.7 (35.7) | 101.9 (36.6) |
| IL | 32.4 (11.8) | 31.8 (12.5) |
| Non‐IL | 70.4 (31.0) | 70.1 (31.8) |
| Total lesion count at baseline, n (%) | ||
| <71 | 37 (21.5) | 41 (23.2) |
| 71–140 | 111 (64.5) | 107 (60.4) |
| <140 | 24 (14.0) | 29 (16.4) |
| ISGA at baseline,† n (%) | ||
| 2 (mild) | 31 (18.0) | 43 (24.3) |
| 3 (moderate) | 114 (66.3) | 113 (63.8) |
| 4 (severe) | 27 (15.7) | 21 (11.9) |
†ISGA is a 6‐point scale ranging from 0 (clear) to 5 (very severe), defined as follows: 0 (clear), clear skin with no IL or non‐IL; 1 (almost clear), rare non‐IL with no more than rare papules; 2 (mild), greater than grade 1, some non‐IL with no more than a few IL (papules/pustules only, no nodular lesions); 3 (moderate), greater than grade 2, up to many non‐IL and may have some IL, but no more than one small nodular lesion; 4 (severe), greater than grade 3, up to many non‐IL and IL, but no more than a few nodular lesions; and 5 (very severe), many non‐IL and IL, and more than a few nodular lesions. May have cystic lesions. ADA, adapalene; BPO, benzoyl peroxide; CLNP, clindamycin phosphate; IL, inflammatory lesion; ISGA, Investigator's Static Global Assessments; ITT, intent‐to‐treat; SD, standard deviation; TL, total lesion.